Effect of CXCR4 and CD133 Co-expression on the Prognosis of Patients with Stage II~III Colon Cancer

Li, Xiaofeng; Guo, Xiaoguang; Yang, Yong-Yan; Liu, Ai-Yong

doi:10.7314/apjcp.2015.16.3.1073

Cited by 9 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the selection criteria, a total of 37 studies published from 2008 to 2016 were eligible for the meta-analysis. [ 2 , 10 – 15 , 18 – 47 ] A total of 5397 CRC patients from China, Japan, South Korea, Italy, Germany, Australia, Spain, and Czech were enrolled. The study sample sizes ranged from 32 to 523 cases.…”

Section: Resultsmentioning

confidence: 99%

CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients

Huang

et al. 2018

Medicine

View full text Add to dashboard Cite

Background:CD133 has been identified as a putative cancer stem cell marker in colorectal cancer (CRC). However, the clinicopathological and prognostic significance of CD133 in CRC patients remains controversial. Thus, we conducted a meta-analysis to quantitatively evaluate the above issues.Methods:We collected a comprehensive literature search from PubMed, Web of Science, and Embase database up to September 20, 2016 examining CD133 and clinical features of colorectal cancer patients. We used the odds ratio (OR) with 95% confidence interval (CI) to estimate the effects by overall and stratified analysis.Results:The overall result of our meta-analysis indicated that CD133 expression was positively correlated with T category, distant metastasis, lymphatic invasion, and vascular invasion. Moreover, patients with higher CD133 expression had a poorer overall survival (OS) (HR=2.01, P < .001) and a lower 5-year OS rate (OR = 3.26, P < .001) than those with lower expression. Disease-free survival (DFS) and 5-year DFS rate were similar with the above results. Though the correlation between CD133 expression with the clinical characteristic was not positive in some ways when we analyzed the different subgroup. The prognostic value of CD133 expression for 5-year OS rate of CRC patients was noticeable in spite of different patients’ region, multiple antibodies used in studies, various cut-off values of CD133 expression, and adjuvant therapy situation of patients.Conclusion:CD133 is a useful predictive or prognostic biomarker for CRC in clinical assessment and may serve as a potential therapeutic target for CRC.

show abstract

Section: Resultsmentioning

confidence: 99%

CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients

Huang

et al. 2018

Medicine

View full text Add to dashboard Cite

show abstract

“…CXCR4, a seven-transmembrane G protein-coupled receptor, is a physiological receptor for stromal-derivedfactor-1 (19) which is highly expressed in various types of human tumors (20)(21)(22)(23)(24). A number of studies have demonstrated the vital role of CXCR4 in cancer cell survival, proliferation, invasion and metastasis, and that CXCR4 promotes EMT processes in various cancers (25)(26)(27)(28)(29), with CD133 + CXCR4 + cells showing a stronger invasiveness capacity (18,(30)(31)(32)(33).…”

Section: Cxcr4 Is Involved In Cd133-induced Emt In Non-small Cell Lunmentioning

confidence: 99%

CXCR4 is involved in CD133-induced EMT in non-small cell lung cancer

Xie

Xiong

et al. 2016

International Journal of Oncology

View full text Add to dashboard Cite

Metastasis is the major cause of death in patients with non-small cell lung cancer (NSCLC), and epithelial-mesenchymal transition (EMT) has been observed to be one of the key regulators of metastasis in certain cancers as it confers an invasive phenotype. CD133 is a widely used cancer stem cell (CSC) marker, and CD133-positive cancer cells are thought to be tumor-initiating cells with CSC characteristics, while CXCR4, a stromal-derived-factor-1 specific chemokine receptor, is highly expressed in NSCLC tissues and participates in cancer progression by regulating cell anti-apoptosis. We previously demonstrated that CXCR4 promotes NSCLC chemoresistance by upregulating CYP1B1, however, the relationship of CD133, CXCR4 and EMT processes in NSCLC metastasis are unclear. In this study, we detected a CD133 and CXCR4 high expression in tissue specimens from 64 NSCLC patients by immunohistochemistry, of which CD133 and CXCR4 were found to be positively associated with metastatic NSCLC patients. CD133 was found to promote NSCLC tumorigenesis and mediated the expression of CXCR4. Furthermore, CD133/CXCR4 co-expression was found to be an independent prognostic factor as shown by univariate and multivariate Cox regression analysis, and was observed to regulate the expression of EMT-related molecules and transcriptional factors in NSCLC. In addition, our results showed that E-cadherin and Vimentin were simultaneously downregulated and upregulated, in CD133+CXCR4+ A549 cells, respectively. While E-cadherin was upregulated and Vimentin was downregulated in metastatic NSCLC patients. Vimentin expression was also observed to have a positive correlation with CD133/CXCR4 co-expression in NSCLC patients and survival analysis results suggested that Vimentin high expression might be significantly associated with poor survival rates of the patients. Thus, these results suggest that the CD133/CXCR4/EMT axis may be a prognostic marker and may provide novel targets for combinational therapies in the treatment of NSCLC.

show abstract

“…The stromal cell-derived factor-1 (SDF-1/CXCR4) axis is involved in delivering signals related to chemotaxis, cell survival and/or proliferation, and thereby plays an important role in EMT and tumor invasiveness [ 43 , 44 ]. The co-expression of CXCR4 and CD133 in colon cancer may be associated with unfavorable prognosis [ 45 , 46 ]. Our data show that PRI-2191, PRI-1907 and PRI-1917 might be used to induce the loss of stem-like phenotype, as well as to decrease chemotactic and proliferative activity of colon cancer cells refractory to the cytoreductive treatment.…”

Section: Discussionmentioning

confidence: 99%

The Effect of Analogues of 1α,25-Dihydroxyvitamin D2 on the Regrowth and Gene Expression of Human Colon Cancer Cells Refractory to 5-Fluorouracil

Neska

Swoboda

Przybyszewska

et al. 2016

IJMS

View full text Add to dashboard Cite

This study aimed to evaluate the capacity of hypocalcemic analogues of 1α,25-dihydroxyvitamin D2 (1,25D2) and 1α,25-dihydroxyvitamin D3 (1,25D3) to inhibit regrowth and regulate the stemness-related gene expression in colon cancer cells undergoing renewal after exposure to 5-fluorouracil (5-FU). All of the tested analogues of 1,25D2 equally potently decreased the clonogenicity and the proliferative activity of HT-29 cells which survived the exposure to 5-FU, but differently regulated gene expression of these cells during their renewal. 1,25D2 and analogues (PRI-1907 and PRI-1917), as well as 1,25D3 and analogue PRI-2191, decreased the relative expression level of several stemness-related genes, such as NANOG, OCT3/4, PROM1, SOX2, ALDHA1, CXCR4, in HT-29/5-FU cells during their renewal, in comparison to untreated HT-29/5-FU cells. The other 1,25D2 analogues (PRI-1906 and PRI-1916) were not capable of downregulating the expression of these stemness-related genes as the analogues PRI-1907 and PRI-1917 did. All of the tested vitamin D analogues upregulated CDH1, the gene encoding E-cadherin associated with epithelial phenotype. Out of the series of analogues studied, side-chain branched analogues of 1,25D2 (PRI-1907, PRI-1917) and the analogue of 1,25D3 (PRI-2191) might be used to target cancer cells with stem-like phenotypes that survive conventional chemotherapy.

show abstract

Effect of CXCR4 and CD133 Co-expression on the Prognosis of Patients with Stage II~III Colon Cancer

Cited by 9 publications

References 24 publications

CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients

CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients

CXCR4 is involved in CD133-induced EMT in non-small cell lung cancer

The Effect of Analogues of 1α,25-Dihydroxyvitamin D2 on the Regrowth and Gene Expression of Human Colon Cancer Cells Refractory to 5-Fluorouracil

Contact Info

Product

Resources

About